Setmelanotide

Setmelanotide is a cyclic peptide MC4R agonist designed with high selectivity for the MC4 receptor over other melanocortin receptor subtypes. This selectivity profile minimizes MC1R-mediated pigmentation effects while maximizing the appetite-suppressing and energy-balancing effects mediated through hypothalamic MC4R.

The compound received FDA approval for treatment of obesity in patients with specific genetic defects in the melanocortin pathway, including POMC (pro-opiomelanocortin), PCSK1 (proprotein convertase 1), and LEPR (leptin receptor) deficiency. These rare monogenic obesity disorders result in impaired MC4R signaling, and setmelanotide provides direct receptor activation to restore pathway function.

The cyclic disulfide-bridged structure provides metabolic stability while maintaining a constrained conformation optimal for MC4R binding. The incorporation of D-amino acids further enhances resistance to proteolytic degradation, enabling once-daily subcutaneous administration.

Clinical studies demonstrated dramatic weight loss in patients with MC4R pathway defects, validating this receptor as a therapeutic target for obesity. Research continues to explore setmelanotide's potential in broader obesity populations and in combination with other metabolic therapies, though MC4R-related side effects including skin hyperpigmentation and spontaneous penile erection require management.